Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smart eye drop tracker aims to boost glaucoma treatment adherence

NCT ID NCT07206628

Knowledge-focused Sponsor: Laboratoires Thea Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 18, 2026 · Updated 2 times

Summary

This study is testing a smart device called CONNECTDROP® that clips onto eye drop bottles to track how often glaucoma patients use their medication. About 200 adults with open-angle glaucoma will use the device and a smartphone app for one year. The goal is to see if the technology helps patients take their drops as prescribed and to understand patterns in adherence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Glaucoma or OHT patients from hospital and/or private practice

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patient (≥ 18 years old), man or woman * Patient with a diagnosis of bilateral open angle glaucoma or OHT * Patients being prescribed with glaucoma eye drops in EASYGRIP® bottle for at least 6 weeks in monotherapy. * Patient willing to participate in the study * Patient who consents for data collection in the frame of the study Exclusion Criteria: * Pregnant and/or lactating woman * Patient receiving another ocular treatment for a chronic condition (i.e. regular instillations for several months) * Protected patient: adult under guardianship, curatorship or other protection legal, deprived of liberty by judicial or administrative decision

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adherence to glaucoma therapy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glaucoma ocular hypertension open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adherence to glaucoma therapy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    15 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AOU Sassari Clinica Oculistica

    RECRUITING

    Sassari, 07100, Italy

  • Ambulatorio Oculistica Ospedale San Carlo di Nancy -GVM-

    NOT_YET_RECRUITING

    Roma, 00165, Italy

  • Centro Corporis Lab

    RECRUITING

    Lecce, 73100, Italy

  • Centro Medico Polispecialistico Di Maita

    RECRUITING

    Catania, Italy

  • Centro Oculistico Ramovecchi S.r.l.

    RECRUITING

    Morrovalle, 62010, Italy

  • Dipartimento di Neuroscienze e Scienze Riproduttive ed Odontostomatologiche, Università degli studi di Napoli Federico II

    RECRUITING

    Naples, Italy

  • Humanitas Gradenigo U.O. Oculistica

    RECRUITING

    Torino, 10153, Italy

  • IRCCS Fondazione G.B. Bietti

    RECRUITING

    Roma, 00184, Italy

  • Ospedale Policlinico S. Martino-IRCCS Clinica Oculistica Università di Genova

    RECRUITING

    Genova, 16132, Italy

  • Ospedale San Donà Piave, Aussl 4 Veneto Orientale, UOC Oculistica

    RECRUITING

    San Donà di Piave, Italy

  • Poliambulatorio Chirurgico Modenese Eyecare Clinic

    RECRUITING

    Modena, Italy

  • Studi Oculistici - Dott. Andrea Bedei

    RECRUITING

    Lucca, 55047, Italy

  • Studio Medico Oculistico Dr.ssa Rosa SCHIAVELLI s.r.l.

    RECRUITING

    Corigliano, Italy

  • Studio Oculistico D'Azeglio

    RECRUITING

    Bologna, 40100, Italy

  • UOSD di Oculistica, Fondazione PTV Policlinico Tor Vergata

    RECRUITING

    Roma, 00133, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.